Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. Issue 1 (2nd January 2017)

• Record Type: Journal Article
• Authors: Geddie, Melissa L.; Kohli, Neeraj; Kirpotin, Dmitri B.; Razlog, Maja; Jiao, Yang; Kornaga, Tad; Rennard, Rachel; Xu, Lihui; Schoerberl, Birgit; Marks, James D.; Drummond, Daryl C.; Lugovskoy, Alexey A.
• Is Part Of: MAbs. Volume 9:Issue 1(2017)
• Page Start: 58
• Page End: 67
• Publication Date: 2017-01-02
• Subjects: Antibody-drug conjugate -- antibody engineering -- antibody fragment -- developability -- liposome -- manufacturability -- protein A binding -- stability; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2016.1259047
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: Antibody-targeted nanoparticles have great promise as anti-cancer drugs; however, substantial developmental challenges of antibody modules prevent many candidates from reaching the clinic. Here, we describe a robust strategy for developing an EphA2-targeting antibody fragment for immunoliposomal drug delivery. A highly bioactive single-chain variable fragment (scFv) was engineered to overcome developmental liabilities, including low thermostability and weak binding to affinity purification resins. Improved thermostability was achieved by modifying the framework of the scFv, and complementarity-determining region (CDR)-H2 was modified to increase binding to protein A resins. The results of our engineering campaigns demonstrate that it is possible, using focused design strategies, to rapidly improve the stability and manufacturing characteristics of an antibody fragment for use as a component of a novel therapeutic construct.